Setmelanotide (Imcivree): Strong Evidence in Rare Obesity, None Beyond It

Setmelanotide, sold as Imcivree, is a prescription peptide used to treat a small number of rare, clearly defined forms of severe obesity. For those specific conditions, the evidence is genuinely strong. But step outside them — to general weight loss, fat loss, or “speeding up your metabolism” in people who do not have these disorders — and there is no credible evidence at all. Both of those facts matter.

What it is

Setmelanotide is a lab-made peptide built from a ring of eight amino acids (the building blocks of proteins). It is modeled on one of the body’s own appetite hormones, alpha-melanocyte-stimulating hormone (alpha-MSH). To make the molecule more stable and powerful, chemists close it into a ring with a disulfide bridge (a chemical link between two sulfur-containing parts) and keep the key active section of alpha-MSH, swapping in a tougher, mirror-image version of one amino acid (D-phenylalanine). Its molecular formula is C49H68N18O9S2 (about 1117 Da, a unit of molecular weight), and the official FDA label name is acetyl-L-arginyl-L-cysteinyl-D-alanyl-L-histidinyl-D-phenylalanyl-L-arginyl-L-tryptophanyl-L-cysteinamide, cyclic (2-to-8)-disulfide, acetate.

Here is how it works. It is a selective agonist (a molecule that switches a receptor on) at the melanocortin-4 receptor (MC4R), a switch in the hypothalamus, the brain region that helps control hunger. Normally, the hormone leptin tells the brain you are full through a chain of signals: leptin to POMC to MC4R. In the rare diseases this drug treats, that chain is broken somewhere early on. Setmelanotide steps in further down the line, flipping the MC4R switch on directly and bypassing the break. The result is less hunger, less eating, and a small bump in the calories the body burns. The drug is about 20 times more active at MC4R than at two closely related receptors (MC3R and MC1R). Its leftover activity at MC1R is why darkened skin shows up as a side effect. Scientists have even mapped the exact shape of the drug locked onto its receptor using cryo-electron microscopy, a way of imaging frozen molecules at very high detail (the structure is filed as PDB 7PIU). It is given as a subcutaneous injection (a shot under the skin).

The claims

The approved, legitimate use is narrow: long-term weight management in specific rare genetic or acquired forms of severe obesity. It is an orphan drug (one approved for a rare disease), not a treatment for everyday obesity, diabetes, or general weight loss. It is also being studied in other genes along the same MC4R pathway and in Prader-Willi syndrome, where the maker reported an early, preliminary hint that it might work in late 2025 — but that was a press-release result, not proof.

The way you are most likely to run into it online or on the gray market is very different: as something for appetite control, fat loss, body recomposition, or a “metabolism” boost in otherwise healthy people. None of those uses have any supporting evidence, and none of them are what the drug was tested or approved for.

The evidence

The human research tells a consistent story: strong for each approved use, and absent for everything else.

The earliest work came from Chen and colleagues (2015), a randomized, double-blind crossover study (one where neither patients nor researchers knew who got the drug, and everyone tried both the drug and a placebo) using a 72-hour continuous subcutaneous infusion in 12 adults with obesity. The calories burned at rest rose about 6.4% (roughly 111 kcal/day) compared with placebo, with the body leaning more toward burning fat, and no worrying changes in heart rate or blood pressure. This was a short, early proof that the mechanism works — nothing more.

The key trials behind the 2020 approval were reported by Clement and colleagues (2020): two single-arm, open-label phase 3 trials (everyone knew they were getting the drug, and there was no separate comparison group) in POMC deficiency (10 patients) and LEPR deficiency (11 patients). Built into them was a blinded stretch where the drug was secretly swapped for placebo to see what happened. At about one year, 8 of 10 POMC patients and 5 of 11 LEPR patients lost at least 10% of their weight, and average hunger scores dropped 27% and 44% respectively. Those are striking numbers, but the trials were tiny, had no real control group, were not blinded overall, and were paid for by the company.

For Bardet-Biedl syndrome (the 2022 expansion), Haqq and colleagues (2022) ran a stronger design: a multi-site, randomized, double-blind, placebo-controlled trial of 38 patients total, 19 in each group, with a 14-week core phase followed by open-label treatment. Among Bardet-Biedl patients aged 12 and older, 32.3% lost at least 10% of their weight by 52 weeks (p=0.0006, meaning the result is very unlikely to be due to chance). The results were unclear in the small group of Alstrom patients, who were removed from the approved use.

The VENTURE trial (Argente and colleagues, 2024) supported lowering the minimum age to 2. It was a one-year, open-label study in 12 children aged 2 to 5 with POMC/LEPR deficiency or Bardet-Biedl syndrome, with an average drop in BMI (a height-to-weight measure) of about 18% at one year.

Most recently, the TRANSCEND trial supported the March 2026 approval for acquired hypothalamic obesity (severe weight gain caused by damage to the hypothalamus, often after a brain tumor or its treatment). It was a randomized, placebo-controlled, 52-week study in 142 patients (94 on the drug, 48 on placebo). BMI fell 15.8% on setmelanotide while rising 2.6% on placebo — a placebo-adjusted difference of 18.4% (p<0.0001). As of this writing, those numbers come from the company’s announcement; the peer-reviewed publication should be checked before treating them as final.

What is missing matters just as much. There are no trials in common (polygenic) obesity — the ordinary kind that comes from many genes and lifestyle — or in people without a specific broken pathway. The single-gene trials are very small and lack control groups. There is limited long-term data on heart, metabolic, and overall safety for a drug meant to be taken for years. And there is a built-in conflict of interest: every key trial was funded by the maker, Rhythm Pharmaceuticals, with company-linked authors, and independent confirmation is scarce because these diseases are so rare. None of that cancels out the approvals — but it is the honest context.

Safety and side effects

The most distinctive side effect is skin darkening (hyperpigmentation), caused by the drug’s leftover activity at the MC1R receptor. In the Bardet-Biedl trial, this happened in roughly 61% of patients, and injection-site reactions in about half. Other common effects include nausea, headache, diarrhea, stomach pain, vomiting, depression, and spontaneous erections.

The official DailyMed label carries several specific warnings. Because the drug revs up the pigment cells in skin, it can darken existing moles and trigger new ones, so a full-body skin exam is required before starting and at intervals during treatment. No treatment-related melanoma (a serious skin cancer) has turned up in the trials, but it is something to watch for. The label also flags problems with sexual arousal (including erections lasting over four hours, which need emergency care), depression and suicidal thoughts (which call for monitoring and stopping the drug if they persist), serious allergic reactions including anaphylaxis (a life-threatening whole-body reaction), and the presence of benzyl alcohol as a preservative (a caution for newborns). The drug has an elimination half-life of about 11 hours (the time it takes the body to clear half of it), and roughly 39% leaves the body unchanged in urine within 24 hours.

The reassuring side: no serious treatment-related problems showed up in the small single-gene trials, and the 2015 infusion study found no harmful effect on the heart or circulation. The catch is that these safety datasets are small and short for a medicine meant to be taken long-term. This is not medical advice; setmelanotide is a prescription drug that needs to be monitored by a doctor.

Legal and regulatory status

Setmelanotide is an approved prescription orphan drug — not a supplement and not a research chemical. The FDA first approved it in November 2020 for POMC/PCSK1 and LEPR deficiency in patients aged 6 and older, then expanded it to Bardet-Biedl syndrome (2022), lowered the minimum age to 2 (December 2024, based on the VENTURE data), and approved it for acquired hypothalamic obesity (19 March 2026, based on TRANSCEND). The EMA (Europe’s drug regulator) authorized it on 16 July 2021 for genetically confirmed Bardet-Biedl syndrome and biallelic POMC (including PCSK1) or LEPR deficiency (meaning both copies of the gene are affected), and the EU label now also covers acquired hypothalamic obesity. Health Canada has reviewed it as well.

For athletes, the situation calls for caution. Setmelanotide is not listed by name on the WADA Prohibited List (the global anti-doping rulebook), and we could not confirm that melanocortin agonists are a named category. But as a peptide that acts on a hormone receptor, it plausibly falls under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), and S0 (Non-Approved Substances) would catch any use outside an approved medical setting. The practical takeaway: treat it as banned and high-risk unless you have a Therapeutic Use Exemption (official permission to use a banned drug for a medical reason), and check the current list — this is our reasoned conclusion from the drug’s class, not a word-for-word entry.

Because it is an injectable peptide, setmelanotide also shows up on the research-chemical gray market, where products are unapproved and not checked for what they contain, how pure they are, or whether they are sterile. Sold or used for general weight loss, it is off-label, unstudied, and — if it is marketed for people to use that way — a misbranded, unapproved drug.

Bottom line

Setmelanotide is a real success story in a very small corner of medicine. For the rare genetic and acquired forms of obesity it was tested and approved for, the evidence is strong: dedicated phase 3 trials, large effects, and clear regulatory approval — tempered by small trials with no control groups and heavy involvement from the maker. For the way most people are likely to come across it — general weight loss in someone who does not have one of these conditions — there is no credible evidence that it helps, and a side-effect profile that is not trivial. The honest read is to keep those two worlds apart.

Evidence grade: 10/10 · Established (within approved rare-disease indications); no credible evidence for general or gray-market weight-loss use.

Sources

• Setmelanotide — StatPearls, NCBI Bookshelf (NBK589641)
• Imcivree (setmelanotide) label — DailyMed
• FDA approves first treatment for weight management for people with certain rare genetic conditions (2020)
• Clement K et al. Efficacy and safety of setmelanotide in POMC and LEPR deficiency, phase 3. Lancet Diabetes Endocrinol. 2020. PMID 33137293
• Chen KY et al. RM-493, an MC4R agonist, increases resting energy expenditure in obese individuals. J Clin Endocrinol Metab. 2015. PMID 25675384
• Haqq AM et al. Setmelanotide in Bardet-Biedl syndrome, phase 3. Lancet Diabetes Endocrinol. 2022. PMID 36356613
• Argente J et al. VENTURE: setmelanotide in children aged 2-5. Lancet Diabetes Endocrinol. 2024. PMID 39549719
• Structures of active MC4R-Gs complexes with NDP-alpha-MSH and setmelanotide. Cell Research. 2021 (PMC8563958)
• PDB 7PIU — setmelanotide-bound MC4R structure
• EMA — Imcivree (setmelanotide) EPAR
• Rhythm Pharmaceuticals — FDA approval of Imcivree for acquired hypothalamic obesity (19 March 2026)
• Rhythm Pharmaceuticals — original FDA approval of Imcivree (2020)
• Rhythm Pharmaceuticals — exploratory phase 2 signal in Prader-Willi syndrome (11 December 2025)
• Markham A. Setmelanotide: First Approval. Drugs. 2021
• Setmelanotide — Wikipedia (CAS, formula, code names)